This is a panelist resource list.
The purpose of this summary is to briefly describe the doctrine referred to as the “corporate practice of medicine” and to identify certain key considerations that a contract drafter should take into account when preparing or analyzing a health care contract or arrangement that may implicate state corporate practice of medicine prohibitions/limitations.
This is a sample vendor business associate agreement regarding HIPAA.
The purpose of this list is to offer a brief introductory outline of the Stark Law, some of its key exceptions, and some points to consider when preparing or reviewing a contract that may be subject to the Stark Law.
This is a list of rules on sharing personal health information.
This is a panelist document list.
The purpose of this checklist is to identify certain key considerations that a contract drafter should consider when a health care provider entity is preparing a contract with one or more physicians.
The purpose of this checklist is to identify certain “standard” and “miscellaneous” terms that a contract drafter should consider when preparing a health care contract.
This is a chart showing the comparison of provincial health information protection legislation in Canada.
This articles discusses the ongoing legal, ethical, and social debate regarding the role, if any, to afford personal privacy in a globalized and electronic public health surveillance system during a pandemic response.
This article uses the top ten considerations as a roadmap for acquirers and their counsel when seeking to acquire a physician practice in the United States.
This is a sample HIPAA policy.
The purpose of this checklist is to identify certain key healthcare-related laws that a contract drafter should consider when preparing a health care provider contract.
The purpose of this checklist is to identify certain provisions/subjects that should be considered in connection with the drafting or analysis of certain “unique services” contracts.
'First Aid for Pharma' is intended for United Kingdom pharmaceutical companies that wish to continue to operate within the European Union structure should the UK choose to leave the EU.
This Wisdom of the Crowd (ACC member discussion) is compiled from questions and responses posted by the IT, Privacy and eCommerce Network on their Forum. It addresses the use of indemnification provisions in Business Association Agreements (BAAs) in the United States.
Learn the Top Ten considerations in-house counsel need to know when handling sensitive Protected Health Information ("PHI") and/or Personally Identifiable Information ("PII") in a healthcare setting in the United States, including the unique set of risks associated with this handling of data.
This Top Ten describes key factors and issues companies should look into and out for when investing in Healthcare in India.
This Quick Overview addresses how the Precision Medicine Initiative (the "PMI") allows targeted therapies to be deployed that are more likely to be efficacious, less likely to lead to adverse side effects, and, in many circumstances, more cost-effective for both the patient and society at large than current approaches to many different illnesses.
A detailed due diligence checklist form licensed from the American Health Lawyers Association, adapted, revised and fully annotated by Ropes & Gray, LLC with assistance from Bloomberg Law editorial staff. The checklist included is a sample for a simple, small-dollar transaction in the United States involving a general healthcare provider or supplier.
In this article, key questions are answered by leading practitioners regarding health care, pharmaceutical, and medical device industry laws and compliance in Italy.
The purpose of this Guidebook is to help the law departments of life sciences and medical devices industry, their affiliates and business associates, clinical researchers (CROs), and third-party vendors focus on the cybersecurity and IP asset protection issues in an accessible and practical way.